Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan,
Cancer Chemother Pharmacol. 2014 Feb;73(2):281-5. doi: 10.1007/s00280-013-2350-3. Epub 2013 Nov 20.
The combination of docetaxel and S-1 (DS) therapy is effective in patients with unresectable gastric cancer and is expected to be a regimen in neoadjuvant setting for advanced gastric cancer. This study was held to evaluate the efficacy and safety of DS followed by surgery.
Patients with resectable gastric cancer received 2 courses of docetaxel 40 mg/m(2) on days 1, 15 and S-1 40 mg/m(2) bid orally on days 1-7, 15-21 every 4 weeks, followed by standard radical gastrectomy. Primary end point was the pathological response rate: rate of tumors in which one-third or more parts were affected.
Fourteen patients were enrolled. Thirteen (92.8 %) patients completed two courses of chemotherapy. Grade 3 adverse events were neutropenia in 3 (21.4 %) patients, anemia in 1 (6.2 %) patient and diarrhea in 1 (6.2 %) patient. There were no grade 4 adverse event and febrile neutropenia. All patients underwent R0 resection, and pathological response was found in 50.0 % of patients. There were no major surgical complications and no treatment-related mortality.
The neoadjuvant chemotherapy with DS was effective for patients with locally advanced gastric cancer with manageable toxicities. Further study to confirm the usefulness of this regimen is needed.
多西他赛联合替吉奥（DS）治疗方案在不可切除的胃癌患者中具有显著疗效，有望成为晚期胃癌新辅助治疗的方案之一。本研究旨在评估 DS 方案新辅助化疗后手术的疗效和安全性。
可切除的胃癌患者接受 2 个周期的多西他赛 40mg/m²，第 1、15 天静脉滴注；替吉奥 40mg/m²，每日 2 次口服，第 1-7 天及第 15-21 天，每 4 周 1 个周期，随后进行标准根治性胃切除术。主要终点为病理缓解率：肿瘤三分之一或更多部分受影响的比例。
共纳入 14 例患者。13 例（92.8%）患者完成了 2 个周期的化疗。3 例（21.4%）患者出现 3 级不良反应，包括中性粒细胞减少症；1 例（6.2%）患者出现贫血；1 例（6.2%）患者出现腹泻。无 4 级不良反应和发热性中性粒细胞减少症。所有患者均行 R0 切除，50.0%的患者病理缓解。无重大手术并发症，无治疗相关死亡。
DS 新辅助化疗对局部进展期胃癌患者有效，毒性可耐受。需要进一步研究来证实该方案的有效性。
